Membrane Feeding Assay to Determine the Infectiousness of Plasmodium vivax Gametocytes

Author(s):  
Jetsumon Sattabongkot ◽  
Chalermpon Kumpitak ◽  
Kirakorn Kiattibutr
2016 ◽  
Vol 10 (6) ◽  
pp. e0004807 ◽  
Author(s):  
Andrés F. Vallejo ◽  
Kelly Rubiano ◽  
Andres Amado ◽  
Amy R. Krystosik ◽  
Sócrates Herrera ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Kazutoyo Miura ◽  
Bruce J. Swihart ◽  
Michael P. Fay ◽  
Chalermpon Kumpitak ◽  
Kirakorn Kiattibutr ◽  
...  

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Yongzhe Zhang ◽  
Fei Liu ◽  
Yan Zhao ◽  
Fan Yang ◽  
Jie Bai ◽  
...  

Abstract Background Plasmodium vivax transmission-blocking vaccines (TBVs) are receiving increasing attention. Based on excellent transmission-blocking activities of the PbPH (PBANKA_0417200) and PbSOP26 (PBANKA_1457700) antigens in Plasmodium berghei, their orthologs in P. vivax, PVX_098655 (PvPH) and PVX_101120 (PvSOP26), were selected for the evaluation of their potential as TBVs. Methods Fragments of PvPH (amino acids 22–304) and PvSOP26 (amino acids 30–272) were expressed in the yeast expression system. The recombinant proteins were used to immunize mice to obtain antisera. The transmission-reducing activities of these antisera were evaluated using the direct membrane feeding assay (DMFA) using Anopheles dirus mosquitoes and P. vivax clinical isolates. Results The recombinant proteins PvPH and PvSOP26 induced robust antibody responses in mice. The DMFA showed that the anti-PvSOP26 sera significantly reduced oocyst densities by 92.0 and 84.1% in two parasite isolates, respectively, whereas the anti-PvPH sera did not show evident transmission-reducing activity. The variation in the DMFA results was unlikely due to the genetic polymorphisms of the two genes since their respective sequences were identical in the clinical P. vivax isolates. Conclusion PvSOP26 could be a promising TBV candidate for P. vivax, which warrants further evaluation. Graphical Abstract


Parasitology ◽  
2005 ◽  
Vol 131 (04) ◽  
pp. 582
Author(s):  
M. VAN DER KOLK ◽  
S. J. DE VLAS ◽  
A. SAUL ◽  
M. VAN DE VEGTE-BOLMER ◽  
W. M. ELING ◽  
...  

2021 ◽  
Author(s):  
Yongzhe Zhang ◽  
Fei Liu ◽  
Yan Zhao ◽  
Fan Yang ◽  
Jie Bai ◽  
...  

Abstract Background: Plasmodium vivax transmission-blocking vaccines (TBVs) have received high attention. PVX_098655 (PvPH) and PVX_101120 (PvSOP26) were predicted to be potential TBV antigens based on the studies of their orthologs in Plasmodium berghei. Methods: Fragments of PvPH (amino acids 22–304) and PvSOP26 (amino acids 30–272) were expressed in the yeast expression system. The recombinant proteins were used to immunize mice to obtain the antisera. The transmission-reducing activities of these antisera were evaluated using the standard membrane feeding assay (SMFA) using Anopheles dirus mosquitoes and P. vivax clinical isolates. Results: The recombinant proteins PvPH and PvSOP26 induced robust antibody responses in mice. With SMFA, the anti-PvSOP26 sera significantly reduced oocyst densities by 92.0% and 84.1% in two parasite isolates, while the anti-PvPH sera did not show evident transmission-reducing activity. Both PvPH and PvSOP26 showed limited gene polymorphisms in the clinical P. vivax isolates. Conclusion: PvSOP26 could be a promising TBV candidate for P. vivax.


Vaccine ◽  
2016 ◽  
Vol 34 (35) ◽  
pp. 4145-4151 ◽  
Author(s):  
Kazutoyo Miura ◽  
Bruce J. Swihart ◽  
Bingbing Deng ◽  
Luwen Zhou ◽  
Thao P. Pham ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document